| Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs) R Rathore, JE McCallum, E Varghese, AM Florea, D Büsselberg Apoptosis 22 (7), 898-919, 2017 | 283 | 2017 |
| GPR35 as a novel therapeutic target AE Mackenzie, JE Lappin, DL Taylor, SA Nicklin, G Milligan Frontiers in endocrinology 2, 68, 2011 | 95 | 2011 |
| The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35 AE MacKenzie, G Caltabiano, TC Kent, L Jenkins, JE McCallum, ... Molecular pharmacology 85 (1), 91-104, 2014 | 79 | 2014 |
| Antagonists of GPR35 display high species ortholog selectivity and varying modes of action L Jenkins, N Harries, JE Lappin, AE MacKenzie, Z Neetoo-Isseljee, ... Journal of Pharmacology and Experimental Therapeutics 343 (3), 683-695, 2012 | 58 | 2012 |
| G-protein-coupled receptor 35 mediates human saphenous vein vascular smooth muscle cell migration and endothelial cell proliferation JE McCallum, AE Mackenzie, N Divorty, C Clarke, C Delles, G Milligan, ... Journal of Vascular Research 52 (6), 383-395, 2016 | 35 | 2016 |
| Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma AM Florea, E Varghese, JE McCallum, S Mahgoub, I Helmy, S Varghese, ... Oncotarget 8 (14), 22876, 2017 | 32 | 2017 |
| Investigation of a role for GPR35 as a novel therapeutic target in cardiovascular disease JE McCallum University of Glasgow, 2014 | | 2014 |
| Does The Method Of Carbohydrate Delivery Affect Marathon Performance?: 1035: May 29 3: 30 PM-3: 45 PM S McCafferty, R Sutherland, C Sloss, H Kirwan, R Ross, J Lappin, ... Medicine & Science in Sports & Exercise 41 (5), 155, 2009 | | 2009 |
